2. Others
  3. Biochemical Assay Reagents
  4. DSPE-PEG2000-OH

DSPE-PEG2000-OH is an absorption enhancer. DSPE-PEG2000-OH reduces the expression levels of ZO-1 and Occludin. DSPE-PEG2000-OH enhances the pulmonary absorption of poorly absorbable macromolecules via the paracellular pathway without altering pulmonary membrane fluidity.

For research use only. We do not sell to patients.

DSPE-PEG2000-OH

DSPE-PEG2000-OH Chemical Structure

Size Price Stock Quantity
25 mg In-stock
50 mg In-stock
100 mg In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

DSPE-PEG2000-OH Related Antibodies

Top Publications Citing Use of Products

1 Publications Citing Use of MCE DSPE-PEG2000-OH

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

DSPE-PEG2000-OH is an absorption enhancer. DSPE-PEG2000-OH reduces the expression levels of ZO-1 and Occludin. DSPE-PEG2000-OH enhances the pulmonary absorption of poorly absorbable macromolecules via the paracellular pathway without altering pulmonary membrane fluidity[1].

In Vitro

DSPE-PEG2000-OH (1% (w/v); 20 min) does not alter the fluidity of isolated rat lung membrane vesicles, as measured by fluorescence polarization using DPH and TMA-DPH probes[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

DSPE-PEG2000-OH Related Antibodies
In Vivo

DSPE-PEG-OH (0.1-2.0% (w/v); intratracheal administration; single dose) significantly enhances the pulmonary absorption of poorly absorbable macromolecules in rats, with a maximum enhancement fold of 4.5-fold for FD10 at the dose of 1.0% (w/v)[1].
DSPE-PEG-OH (0.1-1.0% (w/v); intratracheal administration; single dose; 1.0% (w/v); intratracheal administration; once weekly; for 2 consecutive weeks) does not induce significant local pulmonary membrane damage in brown rats (rats) at doses up to 1.0% (w/v), whether administered as a single intratracheal dose or once weekly for 2 consecutive weeks[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Sprague Dawley (SD) (Male, ~250 g, ~8 weeks old)[1]
Dosage: 0.1% (w/v), 0.5% (w/v), 1.0% (w/v), 2.0% (w/v)
Administration: intrapulmonary; single dose
Result: Increased FD4 Cmax to 1.48 μg/mL, AUC0-240min to 273.34 μg·min/mL, and enhancement ratio to 1.2 at 0.1% dose; increased FD4 Cmax to 3.15 μg/mL, AUC0-240min to 511.90 μg·min/mL, and enhancement ratio to 2.2 at 0.5% dose (p < .01); increased FD4 Cmax to 9.21 μg/mL, AUC0-240min to 1013.99 μg·min/mL, and enhancement ratio to 4.3 at 1.0% dose (p < .01); increased FD4 Cmax to 7.53 μg/mL, AUC0-240min to 937.40 μg·min/mL, and enhancement ratio to 3.9 at 2.0% dose (p < .01).
Increased FD10 Cmax to 1.34 μg/mL, AUC0-240min to 228.92 μg·min/mL, and enhancement ratio to 1.8 at 0.1% dose (p < .01); increased FD10 Cmax to 2.32 μg/mL, AUC0-240min to 374.12 μg·min/mL, and enhancement ratio to 2.9 at 0.5% dose (p < .01); increased FD10 Cmax to 3.78 μg/mL, AUC0-240min to 585.89 μg·min/mL, and enhancement ratio to 4.5 at 1.0% dose (p < .01).
Increased FD70 Cmax to 0.25 μg/mL, AUC0-240min to 37.64 μg·min/mL, and enhancement ratio to 3.7 at 0.5% dose (p < .01); increased FD70 Cmax to 0.25 μg/mL, AUC0-240min to 38.43 μg·min/mL, and enhancement ratio to 3.7 at 1.0% dose (p < .01); showed no significant enhancement for FD70 at 0.1% dose.
Increased calcitonin D% to 30.21, AAC0-240min to 117.42, and enhancement ratio to 3.0 at 1.0% dose (p < .01).
Increased insulin D% to 60.19, AAC0-240min to 12.76, and enhancement ratio to 1.4 at 1.0% dose, with no statistically significant difference compared to control.
Animal Model: Sprague Dawley (SD) (Male, ~250 g, ~8 weeks old)[1]
Dosage: 0.1% (w/v), 0.5% (w/v), 1.0% (w/v) (single dose); 1.0% (w/v) (2 consecutive weekly doses)
Administration: intrapulmonary; single dose; intrapulmonary; weekly; 2 weeks
Result: Showed no obvious lung tissue damage compared to PBS control at all tested single doses, unlike positive control NaDC which caused significant tissue changes.
Exhibited no statistically significant difference in BALF protein and lactate dehydrogenase (LDH) levels compared to PBS control at 4 h post single dose administration.
Showed no statistically significant difference in BALF protein and LDH levels compared to PBS control after 2 consecutive weekly doses of 1.0% (w/v), unlike positive control NaDC which caused a dramatic increase in both markers.
Molecular Weight

2000 (Average)

Appearance

Solid

Color

White to off-white

SMILES

CCCCCCCCCCCCCCCCCC(OC[C@](OC(CCCCCCCCCCCCCCCCC)=O)([H])COP(O)(OCCNC(OCCOCCO)=O)=O)=O.[n]
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
In solvent -80°C 6 months
-20°C 1 month
Solvent & Solubility
In Vitro: 

Ethanol : 100 mg/mL (Need ultrasonic)

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

DSPE-PEG2000-OH Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

DSPE-PEG2000-OHBiochemical Assay Reagentspulmonary membranespulmonary absorptionZO-1paracellular pathwaystight junction-associated proteinsratsDPHtight junction proteinsoccludinmacromoleculesInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
DSPE-PEG2000-OH
Cat. No.:
HY-140741
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB) Italian - IT (251 KB) Korean - KR (251 KB) Portuguese - PT (251 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.